Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1953 3
1954 1
1955 1
1956 6
1957 8
1958 14
1959 5
1961 3
1964 3
1967 6
1970 4
1971 1
1972 2
1973 3
1974 4
1975 7
1976 1
1977 1
1978 1
1979 3
1980 3
1981 1
1982 6
1983 5
1984 12
1985 12
1986 8
1987 5
1988 4
1989 24
1990 17
1991 8
1992 4
1993 9
1994 1
1995 7
1996 8
1997 14
1998 16
1999 18
2000 11
2001 11
2002 6
2003 5
2004 5
2005 2
2006 6
2007 9
2008 9
2009 6
2010 5
2011 4
2012 5
2013 5
2014 8
2015 9
2016 8
2017 7
2018 15
2019 18
2020 10
2021 10
2022 9
2023 15
2024 10
2025 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

467 results

Results by year

Filters applied: . Clear all
Page 1
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Koendgen H, Manfrini M, Belachew S, Hauser SL. Kappos L, et al. Among authors: bernasconi c. JAMA Neurol. 2020 Sep 1;77(9):1132-1140. doi: 10.1001/jamaneurol.2020.1568. JAMA Neurol. 2020. PMID: 32511687 Free PMC article. Clinical Trial.
Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza.
Monto AS, Kuhlbusch K, Bernasconi C, Cao B, Cohen HA, Graham E, Hurt AC, Katugampola L, Kamezawa T, Lauring AS, McLean B, Takazono T, Widmer A, Wildum S, Cowling BJ. Monto AS, et al. Among authors: bernasconi c. N Engl J Med. 2025 Apr 24;392(16):1582-1593. doi: 10.1056/NEJMoa2413156. N Engl J Med. 2025. PMID: 40267424 Clinical Trial.
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A, Thanei GA, Harp C, Bernasconi C, Bonati U, Cross AH, Fischer S, Gaetano L, Hauser SL, Hendricks R, Kappos L, Kuhle J, Leppert D, Model F, Sauter A, Koendgen H, Jia X, Herman AE. Bar-Or A, et al. Among authors: bernasconi c. EBioMedicine. 2023 Jul;93:104662. doi: 10.1016/j.ebiom.2023.104662. Epub 2023 Jun 22. EBioMedicine. 2023. PMID: 37354600 Free PMC article. Clinical Trial.
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
Cerqueira JJ, Berthele A, Cree BAC, Filippi M, Pardo G, Pearson OR, Traboulsee A, Ziemssen T, Vollmer T, Bernasconi C, Mandel CR, Kulyk I, Chognot C, Raposo C, Schneble HM, Thanei GA, Incera E, Havrdová EK. Cerqueira JJ, et al. Among authors: bernasconi c. Neurology. 2025 Feb 25;104(4):e210142. doi: 10.1212/WNL.0000000000210142. Epub 2025 Jan 30. Neurology. 2025. PMID: 39883906 Free PMC article. Clinical Trial.
Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.
Arnold DL, Kolind S, Assemlal HE, Bar-Or A, Inglese M, Kappos L, Parmar K, Sprenger T, Traboulsee A, Vavasour IM, Wolinsky JS, Bernasconi C, Bonati U, Magon S, Tackenberg B, Gaetano L. Arnold DL, et al. Among authors: bernasconi c. Mult Scler. 2025 Jun;31(7):821-832. doi: 10.1177/13524585251325086. Epub 2025 Apr 16. Mult Scler. 2025. PMID: 40237070 Free PMC article. Clinical Trial.
Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials.
Benedict RH, Kappos L, Miller A, Hartung HP, Overell J, Pei J, Dahlke F, Bernasconi C, Koendgen H, Wang Q, Bonati U, Cohan S. Benedict RH, et al. Among authors: bernasconi c. Mult Scler Relat Disord. 2025 Mar;95:106310. doi: 10.1016/j.msard.2025.106310. Epub 2025 Feb 2. Mult Scler Relat Disord. 2025. PMID: 39965438 Free article. Clinical Trial.
[Thrombocythemias (author's transl)].
Tura S, Alimena G, Artusi T, Baccarani M, Bachetti G, Bernasconi C, Betti S, Biagini G, Boccaccio P, Canevari A, Chezzi C, Ciccone F, Grossi A, Guarini A, Gugliotta L, Isacchi G, Laschi R, Mannucci PM, Morfini M, Motta MR, Pareti FI, Ricci P, Rossi A, Rossi-Ferrini PL, Salvaneschi L, Salvidio E, Sessarego M, Zaccaria A. Tura S, et al. Among authors: bernasconi c. Haematologica. 1979 Oct;64 Suppl:179-220. Haematologica. 1979. PMID: 120276 Review. Italian. No abstract available.
Metabolites in the regulatory risk assessment of pesticides in the EU.
Pelkonen O, Abass K, Parra Morte JM, Panzarea M, Testai E, Rudaz S, Louisse J, Gundert-Remy U, Wolterink G, Jean-Lou Cm D, Coecke S, Bernasconi C. Pelkonen O, et al. Among authors: bernasconi c. Front Toxicol. 2023 Dec 19;5:1304885. doi: 10.3389/ftox.2023.1304885. eCollection 2023. Front Toxicol. 2023. PMID: 38188093 Free PMC article. Review.
467 results